Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events
Amanda Nizam, Ryan K. Rader, Alice Tzeng, Wei Wei, Iris Yeong-Fung Sheng, Allison Martin, Christopher Eing Wee, Timothy D. Gilligan, Shilpa Gupta, Moshe Chaim Ornstein
Topics & Concepts
MedicineDiscontinuationCommon Terminology Criteria for Adverse EventsAdverse effectInternal medicineToxicityHazard ratioSurgeryOncologyConfidence intervalBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersRenal cell carcinoma treatment